CD274 and non-small cell lung carcinoma: CheckMate 9LA, a phase 3 RCT, compared first-line nivolumab/ipilimumab and 2 cycles of platinum-doublet induction chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic NSCLC without driver mutations, regardless of PD-L1 expression levels and histology.